Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947096 | 1.00 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL97613 | 0.92 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL25144 | 0.91 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL3976225 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL525558 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL524545 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL3426738 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28036073 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL524835 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1162471 | 0.88 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025224092-A1 | PEPTIDE-BASED RADIOPHARMACEUTICALS FOR NON-INVASIVE IMAGING OF THE FUNCTIONAL LIVER RESERVE | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640240-A1 | PEPTIDE-BASED RADIOPHARMACEUTICALS FOR NON-INVASIVE IMAGING OF THE FUNCTIONAL LIVER RESERVE | Medizinische Universität Innsbruck (AT) | 2025-10-29 | — | — | EP | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118085061-A | Cyclic peptide tyrosine compounds as neuropeptide y receptor modulators | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110099692-B | Cyclic peptide tyrosine compounds as neuropeptide y receptor modulators | 詹森药业有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117295525-A | Cell penetrating peptide conjugates and methods of use thereof | 牛津大学科技创新有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-5854410-A | Oligonucleoside cleavage compounds and therapies | GENTA INCORPORATED (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0542887-B1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INC (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0542928-A4 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INC (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0542928-A1 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INCORPORATED (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0542887-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002641-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002532-A1 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0339695-A2 | A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | KMT2A 2834/4885FABP5 4000/4885FABP7 2688/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885FABP5 4000/4885FABP7 2688/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | KMT2A 1479/4885FABP5 3119/4885FABP7 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.